253 related articles for article (PubMed ID: 8647941)
1. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.
Voelkel NF; Tuder RM; Wade K; Höper M; Lepley RA; Goulet JL; Koller BH; Fitzpatrick F
J Clin Invest; 1996 Jun; 97(11):2491-8. PubMed ID: 8647941
[TBL] [Abstract][Full Text] [Related]
2. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.
Wright L; Tuder RM; Wang J; Cool CD; Lepley RA; Voelkel NF
Am J Respir Crit Care Med; 1998 Jan; 157(1):219-29. PubMed ID: 9445303
[TBL] [Abstract][Full Text] [Related]
3. In situ amplification of 5-lipoxygenase and 5-lipoxygenase-activating protein in allergic airway inflammation and inhibition by leukotriene blockade.
Chu SJ; Tang LO; Watney E; Chi EY; Henderson WR
J Immunol; 2000 Oct; 165(8):4640-8. PubMed ID: 11035107
[TBL] [Abstract][Full Text] [Related]
4. 5-lipoxygenase and FLAP.
Peters-Golden M; Brock TG
Prostaglandins Leukot Essent Fatty Acids; 2003; 69(2-3):99-109. PubMed ID: 12895592
[TBL] [Abstract][Full Text] [Related]
5. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.
Voelkel NF; Tuder RM; Bridges J; Arend WP
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):664-75. PubMed ID: 7946395
[TBL] [Abstract][Full Text] [Related]
7. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
[TBL] [Abstract][Full Text] [Related]
8. An experimental cell-based model for studying the cell biology and molecular pharmacology of 5-lipoxygenase-activating protein in leukotriene biosynthesis.
Gerstmeier J; Weinigel C; Barz D; Werz O; Garscha U
Biochim Biophys Acta; 2014 Sep; 1840(9):2961-9. PubMed ID: 24905297
[TBL] [Abstract][Full Text] [Related]
9. Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling.
Lammers CH; Schweitzer P; Facchinetti P; Arrang JM; Madamba SG; Siggins GR; Piomelli D
J Neurochem; 1996 Jan; 66(1):147-52. PubMed ID: 8522947
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
Titos E; Clària J; Planagumà A; López-Parra M; González-Périz A; Gaya J; Miquel R; Arroyo V; Rodés J
J Leukoc Biol; 2005 Oct; 78(4):871-8. PubMed ID: 16033810
[TBL] [Abstract][Full Text] [Related]
11. A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells.
Kargman S; Vickers PJ; Evans JF
J Cell Biol; 1992 Dec; 119(6):1701-9. PubMed ID: 1469057
[TBL] [Abstract][Full Text] [Related]
12. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats.
Ono S; Westcott JY; Voelkel NF
J Appl Physiol (1985); 1992 Sep; 73(3):1084-92. PubMed ID: 1400021
[TBL] [Abstract][Full Text] [Related]
13. Increased 5-lipoxygenase activating protein in immune-mediated experimental nephritis.
Montero A; Uda S; Kelavkar U; Yoshimura A; Badr KF; Munger KA
J Nephrol; 2003; 16(5):682-90. PubMed ID: 14733414
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
15. Chronic hypoxia activates lung 15-lipoxygenase, which catalyzes production of 15-HETE and enhances constriction in neonatal rabbit pulmonary arteries.
Zhu D; Medhora M; Campbell WB; Spitzbarth N; Baker JE; Jacobs ER
Circ Res; 2003 May; 92(9):992-1000. PubMed ID: 12690037
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia requires 5-lipoxygenase in mice.
Ichinose F; Zapol WM; Sapirstein A; Ullrich R; Tager AM; Coggins K; Jones R; Bloch KD
Circ Res; 2001 Apr; 88(8):832-8. PubMed ID: 11325876
[TBL] [Abstract][Full Text] [Related]
17. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
18. Key role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension.
Ma C; Li Y; Ma J; Liu Y; Li Q; Niu S; Shen Z; Zhang L; Pan Z; Zhu D
Hypertension; 2011 Oct; 58(4):679-88. PubMed ID: 21859965
[TBL] [Abstract][Full Text] [Related]
19. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages.
Coffey MJ; Wilcoxen SE; Peters-Golden M
Am J Respir Cell Mol Biol; 1994 Aug; 11(2):153-8. PubMed ID: 8049076
[TBL] [Abstract][Full Text] [Related]
20. Hyperoxia increases protein mass of 5-lipoxygenase and its activating protein, flap, and leukotriene B(4) output in newborn rat lungs.
Hosford GE; Koyanagi KS; Leung WI; Olson DM
Exp Lung Res; 2002 Dec; 28(8):671-84. PubMed ID: 12490039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
